Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon

IMPORTANCE: Calcitonin gene-related peptide (CGRP) antagonists have demonstrated tremendous promise in migraine management. However, these medications decrease reflex vasodilatory response, which may lead to exacerbation of microvascular disease in susceptible patients, such as patients with Raynaud...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JAMA Netw Open
Päätekijät: Breen, Ilana D., Brumfiel, Caitlin M., Patel, Meera H., Butterfield, Richard J., VanderPluym, Juliana H., Griffing, Leroy, Pittelkow, Mark R., Mangold, Aaron R.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Medical Association 2021
Aiheet:
Original Investigation
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8056280/
https://ncbi.nlm.nih.gov/pubmed/33871613
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2021.7934
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia